TY - JOUR
T1 - What’s new in pulmonary hypertension clinical research
T2 - lessons from the best abstracts at the 2020 American Thoracic Society International Conference
AU - on behalf of the American Thoracic Society Pulmonary Circulation Assembly Early Career Working Group
AU - Sweatt, Andrew J.
AU - Reddy, Raju
AU - Rahaghi, Farbod N.
AU - Al-Naamani, Nadine
N1 - Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work is supported by the following National Institutes of Health (NIH)/National Heart, Lung and Blood Institute (NHLBI) career development awards: K23HL151892 (Dr. Sweatt), K23HL136905, (Dr. Rahaghi), and K23HL141584 (Dr. Al-Naamani). The manuscript content is solely the responsibility of authors and does not necessarily represent the official views of these funding sources.
Publisher Copyright:
© The Author(s) 2021.
PY - 2021
Y1 - 2021
N2 - In this conference paper, we review the 2020 American Thoracic Society International Conference session titled, “What’s New in Pulmonary Hypertension Clinical Research: Lessons from the Best Abstracts”. This virtual mini-symposium took place on 21 October 2020, in lieu of the annual in-person ATS International Conference which was cancelled due to the COVID-19 pandemic. Seven clinical research abstracts were selected for presentation in the session, which encompassed five major themes: (1) standardizing diagnosis and management of pulmonary hypertension, (2) improving risk assessment in pulmonary arterial hypertension, (3) evaluating biomarkers of disease activity, (4) understanding metabolic dysregulation across the spectrum of pulmonary hypertension, and (5) advancing knowledge in chronic thromboembolic pulmonary hypertension. Focusing on these five thematic contexts, we review the current state of knowledge, summarize presented research abstracts, appraise their significance and limitations, and then discuss relevant future directions in pulmonary hypertension clinical research.
AB - In this conference paper, we review the 2020 American Thoracic Society International Conference session titled, “What’s New in Pulmonary Hypertension Clinical Research: Lessons from the Best Abstracts”. This virtual mini-symposium took place on 21 October 2020, in lieu of the annual in-person ATS International Conference which was cancelled due to the COVID-19 pandemic. Seven clinical research abstracts were selected for presentation in the session, which encompassed five major themes: (1) standardizing diagnosis and management of pulmonary hypertension, (2) improving risk assessment in pulmonary arterial hypertension, (3) evaluating biomarkers of disease activity, (4) understanding metabolic dysregulation across the spectrum of pulmonary hypertension, and (5) advancing knowledge in chronic thromboembolic pulmonary hypertension. Focusing on these five thematic contexts, we review the current state of knowledge, summarize presented research abstracts, appraise their significance and limitations, and then discuss relevant future directions in pulmonary hypertension clinical research.
KW - clinical studies
KW - metabolism
KW - pulmonary embolism
KW - pulmonary hypertension
KW - risk stratification and biomarkers
UR - http://www.scopus.com/inward/record.url?scp=85113606622&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85113606622&partnerID=8YFLogxK
U2 - 10.1177/20458940211040713
DO - 10.1177/20458940211040713
M3 - Article
AN - SCOPUS:85113606622
SN - 2045-8932
VL - 11
JO - Pulmonary Circulation
JF - Pulmonary Circulation
IS - 3
ER -